Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Appeal Panel Tells NICE To Revisit Scenesse Rejection

Executive Summary

An appeals panel has upheld some of the objections to NICE’s decision not to recommend Clinuvel’s Scenesse for NHS funding in England. The HTA body’s Highly Specialized Technologies committee will now have to reconsider its guidance in light of the panel’s conclusions. 

You may also be interested in...

Clinuvel Provides EPP Therapy Scenesse To Chinese Patients

Individual patients in China will soon be able to gain access to Scenesse, a groundbreaking therapy for the rare phototoxicity disorder, erythropoietic protoporphyria, under a named patient program, pending the submission of a formal approval application. The product’s developer, Clinuvel, says it is currently awaiting a response on its filing with the Australian regulator and that it has other markets such as Japan in its sights.

Clinuvel Completes Arduous Journey To US Approval Of Scenesse

First-in-class drug for rare disease EPP obtains FDA approval, company plans treatment center-based rollout. Scenesse, on the market in Europe since 2016, has faced reimbursement hurdles.

US FDA Needs More Time To Review Clinuvel’s Scenesse For Phototoxicity

The user fee goal date for the Food and Drug Administration’s review of Scenesse has been put back from July to October to allow more time to examine the therapy’s benefit-risk profile.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts